This guide is the calm version. It explains what Mounjaro actually is, how it works in the body, who it is licensed for, what the common side effects are, and how getting it on the NHS differs from a private prescription depending on where you live in the UK. Every clinical point here is drawn from the UK Summary of Product Characteristics, NICE and the NHS.
What Mounjaro is, in plain language
Mounjaro is the brand name for the active ingredient tirzepatide1. It is given as a once-weekly injection under the skin, and it comes as a pre-filled KwikPen in six strengths, from 2.5 mg up to 15 mg 3. In the UK it is a prescription-only medicine, which means it can only be supplied after a clinician has assessed that it is appropriate for you 9.
It is licensed for two separate purposes. The first is weight management in adults who meet specific body mass index (BMI) criteria. The second is type 2 diabetes. In both cases the Summary of Product Characteristics (SmPC) describes the medicine as an adjunct, meaning it works alongside a reduced-calorie diet and increased physical activity rather than instead of them 1. NICE frames weight-loss medicines the same way, as one part of a wider plan that includes diet, activity and clinical support 7.
Tirzepatide is the first medicine of its kind to act on two gut-hormone receptors at once, which is why it is often described as a dual agonist. If you want the mechanism in detail, our guide on how GLP-1 and GIP medications actually work covers the science, and how Mounjaro works focuses on tirzepatide specifically.
How Mounjaro works
Tirzepatide is a long-acting GIP and GLP-1 receptor agonist2. GIP stands for glucose-dependent insulinotropic polypeptide, and GLP-1 stands for glucagon-like peptide-1. Both are hormones your gut releases when you eat, and both have receptors in the parts of the brain that regulate appetite 2.
By activating these receptors, tirzepatide increases feelings of fullness, reduces hunger and lowers food cravings 2. The SmPC notes that in clinical studies it reduced energy intake and appetite, with the effect on hunger starting in the first week of treatment and increased satiety from around week three 2. It also delays gastric emptying, the rate at which food leaves the stomach, which adds to the sense of fullness after a meal 2.
The NHS describes the same thing in patient language: tirzepatide works for weight loss by reducing your appetite and helping you feel fuller for longer 9. The delay in stomach emptying is most pronounced when you first start and diminishes over time as your body adapts 2. This is also why side effects tend to be strongest early on, a pattern we return to below.
There is a useful detail in the trial data on cravings. The SmPC reports that tirzepatide significantly reduced cravings for fast food, fats, sweets, carbohydrates and starches, but not cravings for vegetables and fruit 2. In other words it does not flatten the desire to eat entirely; it changes the kind of food the brain pushes you towards. The activity of tirzepatide on the GIP receptor is similar to the natural hormone, while its activity on the GLP-1 receptor is lower than the natural GLP-1 hormone 2, which is part of why it behaves differently from a GLP-1-only medicine.
Who Mounjaro is licensed for
For weight management, the SmPC licenses Mounjaro for adults with a starting BMI of 30 kg/m2 or above (obesity), or 27 to under 30 kg/m2 (overweight) when there is at least one weight-related health condition such as high blood pressure, abnormal blood fats, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes 1. That is the licence. Who can actually get it funded on the NHS is narrower, and we cover that in the access section.
The licence is for adults. The safety and effectiveness of tirzepatide in children under 18 have not been established 3. No dose adjustment is needed based on age, sex, race, ethnicity or body weight, and none is required for kidney or liver impairment, though experience in severe impairment is limited and caution applies 3.
Mounjaro is also licensed separately for type 2 diabetes, where it is used to improve blood sugar control 1. If you are weighing it against other options, our guide on Mounjaro versus Wegovy and the wider list of weight-loss treatments put the alternatives side by side.
Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.
Who should not take Mounjaro, or should take care
The only absolute contraindication in the SmPC is a known hypersensitivity to tirzepatide or any of the ingredients in the pen 3. Beyond that, several groups need caution. Tirzepatide has not been studied in people with a history of pancreatitis and should be used with care in that group 5. It has not been studied in severe gastrointestinal disease, including severe gastroparesis, and the same caution applies 5.
It should not be used in pregnancy and is not recommended in women of childbearing potential who are not using contraception 6. Because tirzepatide stays in the body for a long time, with a half-life of around five days, the SmPC advises stopping it at least one month before a planned pregnancy 6. The NHS puts the practical version at stopping at least four weeks before you start trying 9. It is also not used while breastfeeding, as it is not known whether it passes into breast milk 6.
A few other precautions are worth knowing. The gut side effects can cause dehydration, which in turn can affect kidney function, so the SmPC advises taking care to stay hydrated, particularly in older people 5. Cases of food being breathed into the lungs have been reported in people on GLP-1 medicines who had general anaesthesia or deep sedation, because the stomach empties more slowly, so you should tell the team before any operation or procedure that you take tirzepatide 5. The pen also contains a small amount of benzyl alcohol, which can rarely cause allergic reactions 5.
Tirzepatide can slow the absorption of oral contraceptives, so the SmPC advises adding a barrier method or switching to a non-oral method for four weeks when you start and for four weeks after each dose increase 12. If any of these apply to you, they are exactly the kind of thing a prescriber checks before approving treatment.
What to expect: dosing, titration and side effects
Mounjaro is started low on purpose. The SmPC starting dose is 2.5 mg once weekly for four weeks, then an increase to 5 mg once weekly. After that, the dose can be raised in 2.5 mg steps after a minimum of four weeks at the current dose if needed, up to a maximum of 15 mg once weekly 3. The recommended maintenance doses are 5, 10 and 15 mg 3. Our Mounjaro dose guide walks through the titration schedule in more detail.
You inject it under the skin of the abdomen, thigh or upper arm, on the same day each week, at any time of day and with or without food 3. If you miss a dose, you can take it within four days; if more than four days have passed, skip it and return to your usual day 3. Never take two doses to make up for a missed one 9. Our article on what to do if you miss a dose covers the safe steps.
The most common side effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation and abdominal pain 4. In the weight management trials, nausea was reported by around 25 to 29 percent of people on tirzepatide compared with about 9 percent on placebo, and these effects were mostly mild or moderate, occurred mainly during dose increases, and settled over time 4. Less common but important effects include gallstones, and rarely acute pancreatitis 4. The SmPC asks patients to seek immediate medical attention for persistent, severe abdominal pain, which can be a sign of pancreatitis 5. Our full Mounjaro side effects guide and our advice on managing nausea and constipation go further on what is normal and what is not.
A handful of other effects appear in the data. Injection site reactions such as redness and itching were reported in around 8 percent of people in the weight management trials, compared with about 2 percent on placebo, and were mild 4. Tirzepatide produced a small average rise in heart rate of about 2 to 3 beats per minute 4. Hair loss was reported in 4.9 percent of people on treatment versus 1 percent on placebo, was mostly mild, and most people recovered while still on treatment 4. If you also take a sulphonylurea or insulin for type 2 diabetes, the risk of low blood sugar rises, and your prescriber may reduce those doses 5.
Getting Mounjaro: NHS and private access across the UK
There is a gap between what Mounjaro is licensed for and who can get it on the NHS, and the rules differ by nation. This section describes England, Scotland and Wales; Northern Ireland arrangements are still developing. Tirzepatide is available either on the NHS where you meet the criteria, or privately on prescription from a registered pharmacy 9.
In England, NICE recommends tirzepatide for adults with a BMI of at least 35 kg/m2 and at least one weight-related condition, with a threshold reduced by 2.5 kg/m2 for several ethnic groups at equivalent risk 8. NHS access is being phased in over several years through specialist services and primary care. Under the interim commissioning plan, the earliest groups are those with the highest BMI and the most weight-related conditions, with broader eligibility opening from around June 2026 and again from March 2027 8. If less than 5 percent of starting weight is lost after six months on the highest tolerated dose, the prescriber reviews whether to continue 8.
In Scotland, the Scottish Medicines Consortium accepts tirzepatide for restricted use, for adults with a BMI of 30 kg/m2 or above and at least one weight-related condition, provided it is supplied under the agreed patient access scheme 10. In Wales, a Welsh Government circular confirms that for weight loss, tirzepatide should currently only be started through NHS specialist weight management services, with no new initiations elsewhere, while a national approach is worked out 11. The practical result is that many people who do not yet qualify on the NHS look at the private route, which is why understanding the criteria for your nation matters before you assume how you will access it.
Frequently asked questions
Is Mounjaro the same as Ozempic or Wegovy?
No. Mounjaro is tirzepatide, which acts on two receptors, GIP and GLP-1 2. Wegovy and Ozempic both contain semaglutide, which acts on GLP-1 only. Wegovy is the semaglutide brand licensed for weight management, while Ozempic is licensed for type 2 diabetes. For a direct comparison of the two weight-loss injections, see our guide on Mounjaro versus Wegovy.How is Mounjaro stored?
The NHS advises keeping your injection in the fridge until you are ready to use it 9. Storage rules, including how long a pen can spend at room temperature once you start using it, are set out on the pack and leaflet, and we cover them in detail in our guide on Mounjaro storage and room temperature rules. Following them matters because tirzepatide is a temperature-sensitive protein.Can I drink alcohol on Mounjaro?
The SmPC does not list alcohol as a contraindication, but the NHS advises it is best to avoid alcohol while using tirzepatide because it can worsen side effects such as nausea and vomiting 9. Drinking on a settled dose, with food, in moderation is a different situation from drinking during a dose increase. Our dedicated guide on Mounjaro and alcohol works through the practical position.How quickly will Mounjaro work?
The SmPC reports that appetite effects begin early, with reduced hunger from the first week and increased fullness from around week three 2. Weight change is gradual and varies between people, and the dose is increased in stages over the first months. NICE uses a five percent weight loss at six months on the highest tolerated dose as the point to review whether treatment is working for you 8.What happens if I stop taking Mounjaro?
Tirzepatide reduces appetite while you are taking it, so appetite tends to return when you stop, and weight regain is common. The NHS advises not stopping suddenly and talking to your doctor first, particularly if you have type 2 diabetes, because it can affect your blood sugar 9. Our article on why weight regain happens after stopping explains how to minimise it.Your next step
Mounjaro is a genuinely effective tool for weight management when it is the right fit, but it is a prescription-only medicine with real side effects, real contraindications and access rules that vary across the UK. The sensible first move is to find out whether you meet the licensed criteria and whether it suits your medical history.
If you think Mounjaro might be appropriate for you, speak to your GP or pharmacist about NHS eligibility in your nation, or start a consultation with a clinician who can review your medical history and confirm whether treatment is suitable. Bring an honest picture of your health and any other medicines you take, because that is what makes the assessment safe.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
